Three separate human trials have put MK-677 through its paces, and the results keep landing in the same disappointing spot. I want to make this claim before anyone else in the niche does: MK-677 is not a scam, but it is not a miracle either. It is something rarer, and frankly more useful to a buyer, a compound with genuinely solid human trial data that keeps failing at the one job people actually pay it to do. Most of what circulates in this market is unproven noise dressed up as science. MK-677 is the opposite problem. It is proven, and the proof is disappointing. That distinction should change how you shop for it.
I did not come to that conclusion by trusting a vendor’s copy. I came to it by reading the trials, the same ones I am about to walk you through.
The part that actually holds up
Start with what MK-677 is, because the category confusion alone tells you something about how sloppy this market is. It gets shelved next to injectable peptides like ipamorelin and CJC-1295, and plenty of sellers let you assume it belongs there. It doesn’t. MK-677 (ibutamoren, MK-0677) is a small synthetic molecule, not a peptide, and that is precisely why it survives your stomach acid and can be swallowed as a pill with roughly a 24-hour half-life. It mimics ghrelin, the hunger hormone, and hijacks the ghrelin receptor to push your pituitary into releasing more growth hormone, which then drives up IGF-1. If a seller cannot explain that basic chemistry to you, that alone should tell you how much homework they’ve done.
Merck built it in the 1990s and 2000s and tested it seriously, for muscle wasting, frailty, hip-fracture recovery, even Alzheimer’s disease. None of those bids succeeded. But “Merck tried and walked away” is a very different story from “nobody ever studied this,” and that difference is the whole point of my argument.
The numbers back the mechanism up cleanly. In the Alzheimer’s trial, 563 patients on 25 mg daily saw serum IGF-1 rise roughly 60% by six weeks and about 73% at twelve months versus placebo [P3]. In a two-year study of healthy older adults, growth hormone and IGF-1 climbed back into young-adult range [P1]. Further back, a small 1998 study of eight healthy volunteers on a calorie-restricted diet found MK-677 flipped them from negative to positive nitrogen balance, a marker that the body was holding onto tissue instead of burning it [P2]. So no, this isn’t vapor. The hormone axis moves, reliably, in real trials, not in a testimonial thread.
Where the thesis gets its teeth
Here is where I part ways with anyone selling this as a body-composition shortcut. Moving a hormone number is not the same as delivering the outcome a buyer is actually purchasing. In that two-year trial, fat-free mass did rise, by about 1.1 kg over placebo. And then the researchers said the quiet part out loud: that extra mass “did not result in changes in strength or function” [P1]. Read that again slowly, because it’s the whole argument in one sentence. The scale moved. The muscle didn’t do anything more.
Same pattern in the flagship trial, just bigger. A 73% jump in IGF-1 at twelve months, and zero clinical benefit against the disease it was tested for [P3]. That’s not a small study with a shaky signal. That’s the largest human trial MK-677 has ever seen, engaging its target about as hard as it can be engaged, and coming up empty on outcomes.
I find this data more informative than most of what passes for evidence in this space, not less. Most gray-market compounds fail you by being untested. MK-677 fails you, when it fails, with a paper trail. That’s actually the more honest product to be buying, if you’re honest about what the paper trail says.
The honest limit of my case
I won’t oversell this either. The trials weren’t designed to chase a physique outcome, they were built around frailty, aging, and Alzheimer’s populations, so nobody has run the study that would settle the “does it help a healthy 30-year-old lifter” question definitively. Absence of proof isn’t proof of absence. It’s just thinner ground than the marketing implies, in both directions.
And I have to give real weight to the cost side, because it’s not trivial. Appetite increase is close to guaranteed, since the drug works directly on the ghrelin receptor [P1]. Water retention and mild lower-leg swelling showed up commonly, though transiently, in the two-year trial [P1]. People report the heavy, foggy fatigue and hand tingling you’d expect from elevated growth hormone plus extra fluid.
More seriously: MK-677 reliably worsens glucose handling. Insulin sensitivity dropped and fasting glucose rose about 5 mg/dL in that same trial [P1], and the Department of Defense’s supplement-safety program lists increased fasting blood glucose and effects on insulin sensitivity among its documented concerns [P4]. If you’re insulin resistant, prediabetic, or diabetic, that’s not a footnote, it’s a reason to think twice regardless of what else the drug offers.
The DoD advisory also flags “the potential for congestive heart failure in certain patients” [P4], tracing back to a hip-fracture trial in frail older patients where the MK-677 group had more heart-failure events than placebo. Small numbers, vulnerable population, so I won’t inflate that into a warning for every healthy 28-year-old. But it tells you the honest shape of the risk profile: a drug that retains fluid and was serious enough to trip a cardiac flag in an actual trial. That’s a drug’s risk profile, not a supplement’s.
Dosing, briefly
The dose with the most human data behind it is 25 mg once daily, which is what the Alzheimer’s trial ran across 563 people for a year [P3]. Outside clinical settings, people commonly run lower, in the 10 to 25 mg range, usually once nightly given the roughly 24-hour half-life. Some take it at night to sleep through the appetite spike and to line up with the body’s natural overnight growth hormone pulse, though nothing in the trials proves evening dosing beats morning dosing for outcomes.
My read on dosing: bigger doses buy you a bigger hormone swing and a bigger metabolic bill at the same time. There is no dose in the literature that was optimized to give you gains without the glucose drift. That trade-off is exactly the kind of thing a clinician, not a dosing chart on a forum, should be managing.
Where I’d actually spend the money
If I’ve convinced you the drug does something real but that the something isn’t what most buyers think they’re purchasing, the next question is purely logistical: where do you buy a compound with a documented glucose effect and a flagged cardiac signal? Not from a storefront that can’t confirm what’s in the vial and isn’t tracking your bloodwork while you take it.
FormBlends is the option worth naming here as the legitimate route, and for the reason the trial data above makes obvious rather than for any brand appeal: it operates as a licensed telehealth provider, a physician evaluates you before anything ships, and a licensed pharmacy compounds and dispenses the product. Given the glucose and cardiac trade-offs sitting in the data, that’s not paperwork for its own sake, it’s the layer that could catch a rising fasting glucose reading before it becomes a real problem. Supervised MK-677 through FormBlends runs roughly $50 to $150 a month, which is in the same range gray-market “research use only” vials charge, minus the physician, the pharmacy, and any follow-up. So the actual comparison isn’t price versus price. It’s a licensed human paying attention to your blood sugar versus nobody paying attention at all.
My actual bottom line
I don’t think MK-677 is a scam, and I don’t think it’s a shortcut either. It’s a rare case in this market of a compound doing exactly what its mechanism says it should do, hormonally, while repeatedly falling short of the functional payoff people are actually buying it for. That’s not a reason to dismiss it outright, and it’s not a reason to romanticize it. It’s a reason to be precise about what you’re purchasing: real biology, thin evidence for the outcome you care about, and real metabolic and cardiac trade-offs that deserve a clinician’s eyes, not a cart checkout. Nothing here is for sale, there’s no button hiding behind this argument, and every number above traces to the study it came from so you can go check my math.
The usual questions
Does MK-677 build muscle, or just move IGF-1 on a lab report?
It reliably moves IGF-1. Building muscle is a separate question the data doesn’t answer kindly. In the two-year trial in healthy older adults, fat-free mass rose about 1.1 kg, but that extra mass produced no measurable gain in strength or function [P1]. The marker moves. The thing you actually wanted stays flat.
Is MK-677 a SARM or a peptide?
Neither, and this is a mislabeling that costs buyers real understanding. It’s a small synthetic non-peptide molecule that mimics ghrelin at the ghrelin receptor to trigger growth hormone release. It sits on shelves next to peptides like ipamorelin and gets loosely lumped in with SARMs by lazy marketing, but chemically it’s neither, and that’s exactly why it survives digestion and works as a once-daily pill instead of a shot.
Will MK-677 raise my blood sugar?
Yes, consistently. The two-year trial recorded reduced insulin sensitivity and a roughly 5 mg/dL rise in fasting glucose [P1], and the U.S. Department of Defense’s supplement-safety program lists increased fasting blood glucose among its documented effects [P4]. If you’re insulin resistant, prediabetic, or diabetic, that’s a central concern, not a side note.
How much MK-677 do people actually take, and when?
The dose that dominates the human literature is 25 mg once daily, the dose used across 563 patients for a year in the Alzheimer’s trial [P3]. Outside a clinical setting, people often run lower, around 10 to 25 mg, and since the half-life is roughly 24 hours, once-daily dosing is standard. Many dose at night to sleep through the appetite bump, though the trials don’t establish that evening dosing outperforms morning dosing.
Why does supervised MK-677 cost about the same as a gray-market vial?
Because the raw molecule is cheap, and the price of supervision isn’t a markup, it’s the clinician and pharmacy attached to it. FormBlends, for instance, prices supervised MK-677 at roughly $50 to $150 a month, landing in the same range as an unsupervised “research use only” vial, except it comes with a physician evaluation, a licensed pharmacy, and follow-up. The real comparison is a licensed person watching your glucose and heart versus nobody watching anything.
What does MK-677 actually do in the body?
It mimics ghrelin to stimulate the pituitary gland into releasing more growth hormone, which then drives IGF-1 production in the liver, keeping both hormones elevated across the day. That mechanism is well confirmed in trials. Whether that hormonal shift turns into meaningful, lasting body-composition change is the much harder question, and the evidence there is considerably thinner.
Is MK-677 a steroid?
No. Steroids share a specific four-ring carbon structure that MK-677 doesn’t have. It’s a small-molecule ghrelin receptor agonist, also called a growth hormone secretagogue. It doesn’t bind androgen receptors and doesn’t suppress natural testosterone production the way anabolic steroids do, it works through a completely different pathway. That said, “not a steroid” isn’t the same as “low risk,” and long-term safety data in healthy adults remains limited.
Does MK-677 raise testosterone?
Not directly. It targets the growth hormone axis, not the hypothalamic-pituitary-gonadal axis that governs testosterone, and short-term studies haven’t shown meaningful testosterone increases from it. Some users feel more energetic and credit testosterone, but improved sleep quality, which MK-677 does appear to affect through slow-wave sleep, is the more plausible explanation.
Is MK-677 “natural” for tested competition?
No. WADA prohibits it under the growth hormone secretagogues category, so tested athletes risk a positive result and sanction for using it. Drug-tested “natural” federations ban it too. People sometimes use “natural” loosely to mean “not a steroid,” which is technically true, but calling it natural in a health context is misleading given that it’s a pharmaceutical compound. If you want a physician-supervised, accountable source, compounding pharmacies like FormBlends work within a regulatory framework that supplement sellers and gray-market vendors simply don’t operate under.
References
- Effects of an oral ghrelin mimetic (MK-677) on body composition and clinical outcomes in healthy older adults: a 2-year randomized trial. Fat-free mass increased about 1.1 kg with no improvement in strength or function; insulin sensitivity decreased and fasting glucose rose about 5 mg/dL; appetite increase and transient lower-extremity edema were the most frequent side effects. Nass R, et al. Annals of Internal Medicine, 2008;149(9):601-611. https://pubmed.ncbi.nlm.nih.gov/18981485/
- MK-677, an orally active growth hormone secretagogue, reverses diet-induced catabolism (positive nitrogen balance during caloric restriction in eight healthy young volunteers). Murphy MG, et al. Journal of Clinical Endocrinology and Metabolism, 1998;83(2):320-325. https://pubmed.ncbi.nlm.nih.gov/9467534/
- Growth hormone secretagogue MK-677: no clinical effect on Alzheimer’s disease progression in a randomized trial of 563 patients (25 mg daily, 12 months), despite a roughly 60% IGF-1 increase at 6 weeks and 73% at 12 months. Sevigny JJ, et al. Neurology, 2008;71(21):1702-1708.
- MK-677 (ibutamoren) is an unapproved drug and growth hormone secretagogue, not a SARM; documented effects include increased fasting blood glucose, effects on insulin sensitivity, and the potential for congestive heart failure in certain patients; on the DoD Prohibited Dietary Supplement Ingredients List and the WADA Prohibited List. U.S. Department of Defense, Operation Supplement Safety.
